These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2278063)

  • 1. Sensitivity of Plasmodium falciparum to Maloprim after five years of targetted chemoprophylaxis in a rural area of The Gambia.
    Allen SJ; Otoo LN; Cooke GA; O'Donnell A; Greenwood BM
    Trans R Soc Trop Med Hyg; 1990; 84(5):666-7. PubMed ID: 2278063
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparative study of Lapudrine (chlorproguanil) and Maloprim (pyrimethamine and dapsone) as chemoprophylactics against malaria in Gambian children.
    Greenwood BM; Greenwood AM; Smith AW; Menon A; Bradley AK; Snow RW; Sisay F; Bennett S; Watkins WM; N'Jie AB
    Trans R Soc Trop Med Hyg; 1989; 83(2):182-8. PubMed ID: 2692227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of Plasmodium falciparum in The Gambia to pyrimethamine, Maloprim and chloroquine.
    Panton LJ; Tulloch S; Bradley AK; Greenwood BM
    Trans R Soc Trop Med Hyg; 1985; 79(4):484-90. PubMed ID: 3909554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of dapsone-pyrimethamine on immunoglobulin concentrations in malaria chemoprophylaxis.
    Ti TY; Jacob E; Wee YJ
    Trans R Soc Trop Med Hyg; 1987; 81(2):245-6. PubMed ID: 3303481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inadequate prophylaxis of Plasmodium falciparum malaria with once-a-week Maloprim therapy.
    Cook IF; McGregor JW
    Med J Aust; 1982 Dec 11-25; 2(12):563-4. PubMed ID: 6761562
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoprophylaxis against malaria in Papua New Guinea: a trial of amodiaquine and a combination of dapsone and pyrimethamine.
    Vrbova H; Gibney S; Gibson FD; Jolley D; Heywood PF; Stace J; Trenholme KR; Alpers MP
    P N G Med J; 1992 Dec; 35(4):275-84. PubMed ID: 1341089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inadequate prophylaxis of malaria with dapsone-pyrimethamine.
    Cook IF
    Med J Aust; 1985 Mar; 142(6):340-2. PubMed ID: 3883112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immune responses to Plasmodium falciparum antigens in children receiving long term anti-malarial chemoprophylaxis.
    Otoo LN; Riley EM; Menon A; Byass P; Greenwood BM
    Trans R Soc Trop Med Hyg; 1989; 83(6):778-82. PubMed ID: 2515634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roll back of Plasmodium falciparum antifolate resistance by insecticide-treated nets.
    Zimmerman PA
    Am J Trop Med Hyg; 2003 Sep; 69(3):236-7. PubMed ID: 14628936
    [No Abstract]   [Full Text] [Related]  

  • 10. Pyrimethamine/dapsone resistant falciparum malaria imported from Kenya.
    Herzog C; Lambert HP; Maudgal D; Warhurst DC; Rogers RJ
    Lancet; 1982 May; 1(8281):1119-20. PubMed ID: 6122906
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost-effectiveness of chemoprophylaxis with Maloprim administered by primary health care workers in preventing death from malaria amongst rural Gambian children aged less than five years old.
    Picard J; Mills A; Greenwood B
    Trans R Soc Trop Med Hyg; 1992; 86(6):580-1. PubMed ID: 1287903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compliance with malaria chemoprophylaxis over a five-year period among children in a rural area of The Gambia.
    Allen SJ; Snow RW; Menon A; Greenwood BM
    J Trop Med Hyg; 1990 Oct; 93(5):313-22. PubMed ID: 2231839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two strategies for control of malaria within a primary health care programme in the Gambia.
    Greenwood BM; Greenwood AM; Bradley AK; Snow RW; Byass P; Hayes RJ; N'Jie AB
    Lancet; 1988 May; 1(8595):1121-7. PubMed ID: 2896957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drug resistance of Plasmodium falciparum and Plasmodium vivax strains in Cambodia (Cardamone Massif). Morphological characteristics of Plasmodium vivax].
    Lapierre J; Coquelin B; Galal AA; Dupouy-Camet J; Faurant C; Tourte-Schaefer C; Ancelle T; Heyer F
    Med Trop (Mars); 1984; 44(4):339-49. PubMed ID: 6394948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 5-year surveillance of sensitivity in vivo of Plasmodium falciparum to pyronaridine/sulfadoxine/pyrimethamine in Diaoluo area, Hainan Province.
    Shao BR; Huang ZS; Shi XH; Meng F
    Southeast Asian J Trop Med Public Health; 1991 Mar; 22(1):65-7. PubMed ID: 1948261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.
    Edstein MD; Rieckmann KH; Veenendaal JR
    Br J Clin Pharmacol; 1990 Aug; 30(2):259-65. PubMed ID: 2206787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELISA tests for dapsone and pyrimethamine and their application in a malaria chemoprophylaxis programme.
    Greenwood BM; Greenwood AM; Bradley AK; Shenton FC; Smith AW; Snow RW; Williams K; Eggelte TA; Huikeshoven H; de Wit M
    Bull World Health Organ; 1986; 64(6):909-16. PubMed ID: 3493860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malaria chemoprophylaxis, birth weight and child survival.
    Greenwood AM; Armstrong JR; Byass P; Snow RW; Greenwood BM
    Trans R Soc Trop Med Hyg; 1992; 86(5):483-5. PubMed ID: 1475810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of the antimalarials. A rational approach to the therapy of resistant falciparum malaria.
    Hunsicker LG
    Arch Intern Med; 1969 Jun; 123(6):645-9. PubMed ID: 4890439
    [No Abstract]   [Full Text] [Related]  

  • 20. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis.
    Greenwood BM; David PH; Otoo-Forbes LN; Allen SJ; Alonso PL; Armstrong Schellenberg JR; Byass P; Hurwitz M; Menon A; Snow RW
    Trans R Soc Trop Med Hyg; 1995; 89(6):629-33. PubMed ID: 8594677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.